Analysis of the pharmacological mechanisms of Xiaoyao pill in breast cancer treatment.

Abstract

Objective: The Xiaoyao pill, a Chinese patent medicine initially designed for treating breast hyperplasia, has emerged as a potential therapy for inhibiting breast cancer.

Method: Research has delved into its mechanisms, utilizing Disease Oncology, Gene Oncology, and Kyoto Encyclopedia of Genes and Genomes analyses. Correlations between Xiaoyao pill's target genes and lipid metabolism were identified. Comparative gene set enrichment analysis between normal and breast cancer (BRCA) tissues showed down-regulation of lipid metabolism-related genes in BRCA, suggesting their role in cancer development. Weighted gene co-expression analysis revealed a gene module associated with both normal and malignant breast tissue, impacting lipid metabolism significantly.

Result: Protein-protein interaction network analysis highlighted expression differences in 24 common genes shared between Xiaoyao pill and BRCA. Receiver operating characteristic curve analysis indicated Xiaoyao pill's potential diagnostic utility for BRCA. Target genes were detectable in immune cell types, particularly T cells, suggesting a role in tumor immunity modulation.

Conclusion: In conclusion, the Xiaoyao pill holds promise in treating BRCA by down-regulating lipid metabolism pathways and potentially influencing tumor immunity, presenting a multifaceted approach to breast cancer management.